- 1 Combination of QTL and GWAS to uncover the role of phosphodiesterases in
- 2 ischemic heart disease
- 3 Jun Xiao, M.D., Ph.D ^{1,2}, Ziting Gao, M.D. ³, Hongye Wei, M.D. ³, Yajing Wei, M.D. ³,
- 4 Ziyi Qiu, M.D. ³, Wuqing Huang, M.D., Ph.D ³
- ¹ Department of Cardiovascular Surgery, Fujian Medical University Union Hospital,
- 6 Fuzhou, Fujian, China.
- ² Fujian Provincial Clinical Research Center for Cardiovascular Diseases Heart Center of
- 8 Fujian Medical University, Fuzhou, Fujian, China.
- 9 ³ Department of Epidemiology and Health Statistics, School of Public Health, Fujian
- 10 Medical University, Fuzhou, Fujian, China.
- *Corresponding author: Wuqing Huang
- 12 Fujian Medical University,
- No 1, Xue Yuan Road, University Town, 350108
- 14 Fuzhou City, Fujian Province, China.
- 15 Email: wuqing.huang@fjmu.edu.cn
- 16 Telephone: +8617338896101
- 17 **Short title:** Phosphodiesterases and ischemic heart disease
- Word count: abstract (246), main text (3403), figures (5)
- 19 **Abbreviations:** CHD, coronary heart disease; CI, confidence interval; CpG, Cytosine-
- 20 guanine dinucleotides; eQTLs, expression quantitative trait loci; GWAS, genome-wide
- 21 association study; HEIDI, heterogeneity in dependent instruments; mQTL, Methylation
- 22 quantitative trait loci; MI, myocardial infarction; OR, odds ratio; PDE,
- 23 phosphodiesterase; SNP, single-nucleotide polymorphism; SMR, summary-data-based
- 24 Mendelian Randomization.

Abstract

25

- 26 Background: Phosphodiesterases (PDEs) are regarded as important therapeutic targets for
- 27 multiple diseases, and the cardiovascular benefits of several PDE inhibitors have received
- 28 extensive interests.
- 29 **Objectives:** To explore the relationship between genetically-predicted PDEs and
- ischemia heart disease via drug target Mendelian Randomization (MR) approach.
- 31 **Methods**: The expression of genes encoding PDEs was used to proxy the level of PDEs,
- and available quantitative trait loci of gene expression and DNA methylation (eQTLs and
- mQTLs) for each target gene were identified as the genetic instruments. Coronary heart
- disease (CHD) and myocardial infarction (MI) were the outcomes. Summary-data-based
- 35 MR method was used to generate the estimates and two-step MR analysis was applied to
- investigate the mediation of metabolic traits.
- 37 **Results:** MR analyses identified two types of PDEs, PDE5 and PDE8, genetically-
- predicted expression in blood of the encoded genes was significantly associated with the
- 39 risk of CHD (OR_{PDE5A}=1.22,95% CI=1.06-1.40; OR_{PDE8A}=1.26,95% CI=1.07-1.49) and
- 40 MI (OR_{PDE5A}=1.27,95% CI=1.09-1.48; OR_{PDE8A}=1.24,95% CI=1.04-1.48). Especially,
- 41 the highest expression of PDE5A was observed in artery aorta, which was also positively
- 42 related to CHD (OR=1.17,95% CI=1.05-1.32) and MI (OR=1.15,95% CI=1.02-1.30).
- Besides, the methylation level of 12 CpG sites showed a relation with CHD or MI via
- 44 affecting PDE5A expression. The observed association between PDE5A expression and
- 45 outcomes were partly mediated by blood pressure and LDL cholesterol, and the
- 46 association with MI were mostly mediated by CHD (Proportion-mediated: 78.84%).
- 47 **Conclusions:** This study provided genetic evidence about the protective role of PDE5
- 48 inhibition against ischemic heart disease, especially in preventing patients with CHD
- 49 from developing MI.
- Keywords: phosphodiesterases, coronary heart disease, myocardial infarction, Mendelian
- 51 randomization.

Introduction

Phosphodiesterases (PDEs), a family of enzymes from PDE1 to PDE11, are well-known to play a critical role in the regulation of intracellular signaling via hydrolyzing cyclic nucleotides cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine monophosphate (cGMP)(1). The cAMP and cGMP are the second messengers linking to a series of physiological processes, thus PDEs are regarded as important therapeutic targets for multiple diseases (2). Although the PDE families are structurally related, the molecular diversity makes them functionally distinct (2). Some PDE inhibitors have been widely used in clinical practice, and emerging evidence indicates that PDE inhibitors have the potential to be developed or repurposed for a wide range of clinical applications (2,3).

The cardiovascular benefits of PDE inhibitors have received extensive interests in recent decades, for example, accumulating epidemiological studies suggested that PDE5 inhibitors could enhance contractile function for patients with heart failure, improve the prognosis in patients with coronary heart disease, reduce ventricular arrhythmias, and so on (4-16). Coronary heart disease (CHD) is the most common type of cardiovascular diseases, and myocardial infarction (MI) is a major cause of death worldwide. Since 1960s, cAMP and cGMP were found to inhibit platelet aggregation and a group of PDE inhibitors were considered as anti-platelet agents, for instance, dipyridamole (PDE3 inhibitor) has been approved for secondary prevention of ischemic stroke (17). PDE inhibitors were also reported to ameliorate some established risk factors of coronary heart disease, such as metabolic syndrome, a cluster of several metabolic disorders (18). Although these evidence have suggested the cardiovascular benefits of PDE inhibitors, there is a paucity of studies comprehensively exploring the causal effect of PDE inhibitors on CHD or MI.

Randomized clinical trial (RCT) is recognized as the gold standard to confirm the causal effect, however, RCT is not always feasible due to the difficulty of implementation. Mendelian randomization (MR) is thus developed for causal inference by using genetic variants as instruments. Previous studies have applied drug-target MR method to explore the potential drug targets by using quantitative trait loci (QTLs) as

instruments, which are genetic variants associated with quantitative traits, such as gene expression (eQTL), protein (pQTL), methylation (mQTL), et al(19,20).

Therefore, in this study, we aimed to investigate the role of PDEs on CHD and MI by using available eQTLs and mQTLs of genes encoding PDEs as instruments via MR approach and explore how the identified PDEs affect the outcome through metabolic traits.

Methods

Study design

The design of the study was summarized in **Figure 1**. In the primary analysis, we comprehensively investigated the causal effect of the expression of genes encoding PDEs on the risk of CHD or MI by using eQTLs from blood as instruments. For significant MR associations, we further conducted a series of secondary analyses. Firstly, the observed significant associations were examined by using eQTLs in artery or heart tissues as instruments. Secondly, it is known that DNA methylation plays an important role in regulating gene expression, thus we further investigated the relationship between methylation level of related genes encoding significant PDEs and the outcomes by using mQTLs in blood as instruments. Thirdly, two-step MR analysis was used to explore if metabolic traits perform a mediating role between the identified PDEs and the outcomes, including body mass index (BMI), blood pressure, blood lipids and blood glucose.

Summary-level data from publicly available genome-wide association studies (GWASs), expression and methylation quantitative trait loci (eQTLs and mQTLs) studies, were used in this study, all of which have been approved by the relevant institutional review boards with informed consents from participants. Details of data resources are presented in **Supplementary Table 1**.

Selection of genetic instruments

We used the expression of the encoded gene to proxy the level of each PDE, and eQTLs for related genes were used as instruments of gene expression. Given that data of eQTLs in blood are most comprehensive and top eQTLs are highly correlated between blood and other tissues, eQTLs in blood were used to generate genetic instruments to identified

significant PDEs in the primary analysis. For significant associations, we provided additional evidence by using eQTLs in disease-related organs (ie., artery and heart tissues) as instruments. Summary-level data of eQTLs in blood and tissues were obtained from eQTLGen Consortium (N=31,684) and GTEx Consortium V8 (Artery Aorta: N=387; Artery Tibial: N=372; Heart Atrial Appendage: N=584), respectively (21,22). And common SNPs significantly associated with the expression and the methylation in blood for related genes were identified and used to generate instruments of the level of methylation, summary data of mQTLs were selected from a meta-analysis of two cohorts (N=1,980) (23). To reduce weak instrument bias, we only included cis-QTLs (i.e., QTLs within 1 \(\subseteq Mb \) windows from the region of the encoded gene). Hence, common cis-eOTLs or cis-mQTLs (minor allele frequency (MAF) >1%) significantly associated with the expression or methylation of PDEs were identified, in which p<5.0 $\square \times \square 10^{-8}$ was set as the significant threshold to select cis-eQTLs or cis-mQTLs in blood and the threshold of p<1.0 $\square \times \square 10^{-5}$ was used to select cis-eOTLs in tissues due to the limited number of available cis-eOTLs in tissues and the relatively small sample size of original studies. The most significant cis-eQTL or cis-mQTL for each gene was finally selected as the genetic instrument. The coefficient obtained from eQTL or mQTL study is equivalent to 1-SD change of the level of gene expression or DNA methylation for each additional effect allele. The details of QTLs data are presented in **Supplementary Table 1.**

Outcome sources

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

The outcome is ischemic heart disease, including CHD and MI. The GWAS summary-level data for CHD (cases: N=60,801; controls: N=123,504) and MI (cases: N=43,676; controls: N=128,199) were obtained from the CARDIoGRAMplusC4D Consortium with meta-analyses of 48 GWASs, in which the study population was predominantly individuals with European ancestry (24). Metabolic traits were considered as the potential mediators: summary data of GWAS for systolic and diastolic blood pressure was obtained from the International Consortium of Blood Pressure; data for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) obtained from the Global Lipids Genetics Consortium; data for body mass index obtained from the GIANT Consortium; data for fasting blood glucose

obtained from the MAGIC Consortium. The details of GWASs data are presented in

Supplementary Table 1.

Statistical analyses

Effect estimates were generated by using summary-data-based MR (SMR) method, which was recently developed to evaluate the association of quantitative trait and outcome combining summary-level data from QTL and GWAS studies (25). F-statistic was calculated to assess the strength of genetic instruments, an F-statistic of >10 indicates a small role of weak instrument bias in the results (26). The heterogeneity in dependent instruments (HEIDI) test was applied to assess if linkage disequilibrium played a role in the observed association of gene expression or methylation with outcome of interest, in which p value <0.01 indicates that association may be due to linkage. One SNP probably regulates the expression of more than one genes, resulting in the presence of horizontal pleiotropy. To evaluate the potential impact of horizontal pleiotropy, genes near the instrumental variant (within a 1Mb window) were identified if the expression was significantly associated with the variant. Then SMR analysis was conducted to examine if the instrumental variant affected the risk of outcomes via regulating the expression of nearby genes.

Inverse-variance weighted mendelian randomization (IVW-MR) method was applied to obtain the estimates of the causal associations between metabolic traits and the outcome. To evaluate if the significant association between PDE and outcome was mediated by metabolic traits, we conducted a two-step MR study between PDE, candidate mediators, and incident outcome. Two-step MR, also known as network MR, is similar to the approach calculating the product of coefficients (27). We first calculated two MR coefficients: the association between PDE and the mediator (beta1) and the association between the mediator and the outcome (beta2), then multiplied two coefficients to estimate the indirect effect (beta1*beta2). The total effect was estimated by MR coefficient of PDE on the outcome (beta0) and the direct effect was calculated by the difference between total effect and indirect effect (beta1*beta2). Proportion of mediated effect was calculated by the formula of (beta1*beta2)/beta0. P-value of <0.05 was considered as statistical significance. To account for multiple testing correction,

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

Bonferroni correction was also used to adjust the thresholds of significance level, with a strong evidence of P<0.05/(number of genes) and a suggestive evidence of 0.05/(number of genes)<=P<0.05. All analyses were conducted by using SMR software (version 1.03) or R software (version 4.1.0). Results **Genetic instrument selection** As shown in **Figure 1 and Supplementary Table 2**, a total of 7,737 SNPs significantly associated with the expression in blood of 17 genes encoding PDE1 to PDE9 were identified. While there is a lack of available cis-eQTLs identified for PDE10 and PDE11, thus these two PDEs were not included in the analyses. The most significant cis-eQTL for all 17 encoded genes had F statistics of >10, indicating a small role of weak instrument bias in our study. Approved or investigational drugs targeting PDEs are presented in Supplementary Table 2. MR analysis between the expression of genes encoding PDEs in blood and outcomes As shown in Figure 2 and Supplementary table 3, the most significant association with the risk of both CHD and MI was found on PDE5A expression, in which a 1-SD increase of PDE5A expression was associated with increased risk of CHD with an OR of 1.22 (95% CI=1.06-1.40, $P\Box=\Box 0.0046$) or MI with an OR of 1.27 (95% CI=1.09-1.48, $P \Box = \Box 0.0024$). The observed association with MI kept significant after bonferroni correction using a significance threshold of $P\square < \square 0.003$ (multiple testing for 17 genes) and HEIDI test suggested a small role of linkage disequilibrium in the observed association (P_{CHD}=0.160; P_{MI}=0.375). Besides, MR analysis provided a suggestive evidence for a positive association between PDE8A expression and the risk of CHD (OR=1.26, 95% CI=1.07-1.49, P = 0.0047) and MI (OR=1.24, 95% CI=1.04-1.48, $P \Box = \Box 0.0175$), which tended to null after bonferroni correction and HEIDI test in MI analysis showed the potential presence of linkage disequilibrium (P<0.01). As shown in Supplementary Table 5, six genes were identified nearby the instrumental variant of PDE5A expression in blood (rs10518336) and the expression of which were significantly

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

related to the instrumental variant. Among them, the expression of four genes were associated with the risk of outcomes, indicating that the horizontal pleiotropy may not be ruled out (Supplementary Table 6). No association was observed between the expression of gene nearby the instrumental variant of PDE8A expression in blood (rs67804993) and the outcomes (**Supplementary Table 6**). MR analysis between the expression of PDE5A or PDE8A in artery or heart tissues and outcomes As MR analyses found a strong evidence for the association between the expression of PDE5A or PDE8A and the risk of CHD and MI, we further examine the association of PDE5A/PDE8A expression in relevant tissues with outcomes. Heart and artery are the predominating organs in cardiovascular diseases. Supplementary Figure 1 and 2 display the tissue-specific expression of PDE5A and PDE8A from GTEx Portal. PDE5A was expressed highest in artery aorta, followed by artery tibial, and the expression in artery coronary ranked six place, indicating an important role of PDE5 in artery. While PDE8A was expressed highest in nerve tibial, and the expression in artery tibial ranked 15 place. There were 188, 13 and 9 cis-eQTLs identified to generate instruments for PDE5A expression in artery aorta, artery tibial and heart atrial appendage respectively, and 2 ciseQTLs were identified as instruments for PDE8A expression in artery tibial (**Figure 1**). As shown in **Figure 3 and Supplementary table 4**, the associations between PDE5A expression and the outcome were also found in artery aorta (OR_{CHD}=1.17, 95% CI=1.05-1.32, $P \square = \square 0.0066$; $OR_{MI} = 1.15$, 95% CI = 1.02 - 1.30, $P \square = \square 0.0269$) and heart atrial appendage (OR_{CHD}=1.20, 95% CI=1.02-1.41, P = 0.0312; OR_{MI}=1.18, 95% CI=0.99-1.40, P = 0.0667). The observed association with CHD passed the bonferroni correction test ($P \square < \square 0.013$, multiple testing for 4 genes) and the HEIDI test (P > 0.01). No nearby genes were found to be significantly related to the instrumental variant of PDE5A expression in artery aorta (rs1393966) (**Supplementary table 5**). No association was observed between the expression in heart atrial appendage of gene nearby the instrumental variant of PDE5A expression (rs75098287) and the outcomes

230 (Supplementary Table 6). These results suggesting a small role of the horizontal 231 pleiotropy in the observed associations. MR analysis between the methylation of PDE5A or PDE8A in blood and outcomes 232 There were 1,185 and 310 cis-mQTLs in blood identified to generate instruments of DNA 233 234 methylation in 14 CpG sites of PDE5A and 12 CpG sites of PDE8A, respectively (Figure 1). Among these CpG sites, the methylation level of 12 CpG sites of PDE5A and 7 CpG 235 236 sites of PDE8A robustly associated with the expression of the corresponding gene had 237 significant associations with the risk of CHD and MI in the same direction, indicating that methylation in these CpG sites may affect the outcomes via regulating gene 238 239 expression(Figure 4, Supplementary table 7 and 8). 240 Two step MR analyses between PDE5A expression, metabolic traits and outcomes As shown in **Supplementary table 9**, the expression of PDE5A but not PDE8A was 241 related to multiple metabolic traits, thus two step MR analyses were performed to explore 242 the causal relationship between PDE5A expression, metabolic traits and the risk of CHD 243 244 or MI. Figure 5 showed that the association between PDE5A expression and CHD or MI was partly mediated by diastolic blood pressure (Proportion-mediated _{CHD}=25.97%; 245 Proportion-mediated _{MI}=21.42%), systolic blood pressure (Proportion-mediated _{CHD} 246 =15.77%; Proportion-mediated _{MI} =11.63%) and LDL-C (Proportion-mediated _{CHD} 247 248 =15.35%; Proportion-mediated $_{\rm MI}$ = 8.17%). The association between PDE5A expression and MI was mostly mediated by CHD (Proportion mediated=78.84%). No mediated role 249 250 of body mass index, blood glucose or other lipids was observed between PDE5A 251 expression and outcomes. **Discussion** 252 To investigate the therapeutical potential of PDE inhibitors for ischemic heart disease and 253 the underlying pathways, we explored the association of the expression of genes 254 255 encoding PDEs (i.e., PDE1-PDE9) with the risk of CHD and MI in this MR study. Two 256 types of PDEs, PDE5 and PDE8, were identified to have the potential to be repurposed 257 for CHD or MI prevention in this study. Specifically, a strong evidence was observed for 258 the positive association of PDE5A expression in blood and artery agrta (the tissue with highest expression) with the risk of CHD and MI. We also identified 12 CpG sites, the methylation level of which was significantly related to the risk of CHD and MI via affecting the PDE5A expression. Mediation analysis suggested that PDE5 inhibition might reduce the incidence of ischemic heart disease partly through regulating blood pressure and LDL cholesterol. These findings provided genetic evidence that PDE5 inhibitors may be effective in the prevention of CHD and MI, especially in protecting against MI among patients with CHD.

PDE5, encoded by PDE5A gene, is an enzyme selectively hydrolyzing cGMP, which is distributed across most tissues of human body. Thus, it is known that PDE5 inhibitors, including sildenafil, vardenafil and tadalafil, exert its therapeutic effect by inhibiting cGMP degradation. PDE5 inhibitors were originally developed to treat angina while failed in clinical trials, then repurposed and approved by FDA for treating erectile dysfunction in 1998, pulmonary arterial hypertension in 2005 and benign prostatic hyperplasia in 2011 (4-6). Given of the safety of PDE5 inhibitors and the involvement of cGMP in vast physiological processes, enormous interest has been raised to explore the potential new functions of PDE5 inhibitors(6).

Growing preclinical studies have reported that PDE5 inhibitors play a protective role against cardiovascular diseases, such as heart failure, MI, ischemia-induced ventricular arrhythmias, myocardial hypertrophy and so on (4-6). Several clinical trials have demonstrated the benefits of PDE5 inhibitors in patients with heart failure, while the effect on ischemic heart disease is still uncertain (28). A number of observational studies have reported the protective effect of PDE5 inhibitors on ischemic heart disease (29-31). For example, a nationwide Danish cohort study including 71,710 men found that PDE5 inhibitors use was related to a decreased incidence of MI as compared to the general male population without receiving PDE5 inhibitors (RR=0.74; 95% CI=0.69-0.79), however indication bias may play a role in the observed association (31). Another case-control study including type 2 diabetic men with silent coronary heart disease found that treatment with PDE5 inhibitors and statins was negatively associated with the occurrence of major adverse cardiac events (HR=0.66, 95% CI=0.46-0.97), while in which the effect of statins and PDE5 inhibitors cannot be distinguished and indication bias cannot be eliminated as well(30). A recent real-world study based on Swedish nationwide registers

291

292

293

294

295

296

297298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

investigated the protective effect by comparing the survival between men treated with PDE5 inhibitors and those treated with alprostadil in order to reduce the influence from indication bias, since erectile dysfunction is the major indication of PDE5 inhibitors and alprostadil is another treatment for erectile dysfunction(29). This study included 18,542 men with stable coronary heart disease and found that men treated with PDE5 inhibitors had a lower mortality as well as a reduced incidence of major adverse cardiac events, including MI (HR= 0.81, 95%CI=0.70–0.93). Although indication bias can be reduced as much as possible by using active comparator, it is impossible to be completely avoided and unknown confounders cannot be ruled out in observational studies. Besides, as these drugs were mainly prescribed for men to treat erectile dysfunction in real world, it is unlikely to assess the effect in general population. Our study observed consistent results that increased expression of PDE5A was related to a higher risk of CHD and MI, which provided strong supportive evidence for findings from previous observational studies. Besides, we found that the mediated proportion of CHD on the positive relation between PDE5 and MI risk was as high as round 80%, indicating that PDE5 inhibition probably contributed to preventing patients with CHD from MI. Furthermore, PDE5 has been emerged as novel target for treating metabolic disorders, which are known risk factors of ischemic heart disease (18). This study also observed a mediated effect of blood pressure and LDL cholesterol between PDE5 inhibition and ischemic heart disease, which offered some clues for the underlying mechanisms, calling for further studies.

PDE8 was also identified in this study, the inhibition of which was recently found to be a potential novel therapeutic target of treating airway diseases and dementia (32,33). No studies reported the cardiovascular effect of PDE8. Although this MR study found that the expression in blood of PDE8A was related to the risk of CHD and MI, the association did not pass the bonferroni correction test. Besides, PDE8A was expressed less in cardiovascular organs and no relationship was observed between the PDE8A expression in artery and the outcomes. Therefore, whether PDE8 inhibition really had a cardiovascular benefit need to be further investigated.

This is the first MR study to comprehensively explore the causal effects of PDEs on ischemic heart disease. The use of QTLs as instruments to proxy drug exposure in MR study could overcome the shortcomings of observational studies, such as confounding

bias and reverse causation. Besides, several types of OTLs (eOTLs in blood, artery aorta and heart, mQTLs in blood) have provided consistent evidence, indicating the robustness of the protective effect of PDE5 inhibition on ischemic heart disease. Two-step MR analysis contributed to identifying the subgroup population that may benefit more from PDE5 inhibitors use. However, there are several limitations. Firstly, this study used the expression of drug target genes to proxy drug exposure, which might not be equivalent to clinical treatment because of a gap between drug targets and available agents, for example, there may be various effects across different types of PDE5 inhibitors. However, these findings could provide additional evidence for previous observational studies regarding the preventive effect of PDE5 inhibitors against ischemic heart disease. Hence, RCTs are required to further investigate the efficacy of different PDE5 inhibitors. Secondly, horizontal pleiotropy cannot be excluded when using eQTLs in blood as instruments for PDE5A expression in primary analysis, while consistent associations were observed using eQTLs in tissues or mQTLs in blood as instrument, suggesting the robustness of the findings. Thirdly, false negative association of other PDEs cannot be ruled out in drug target MR study as there may be unidentified eQTLs which play a more important role in gene expression than the identified top eQTL. Fourthly, this study was conducted based on summary-level data, thus we were unable to explore the specific effect in subgroup population, such as in men and women. Fifthly, genetic data of this study were mainly collected from population of European ancestry, leading to a limited generalization of these findings.

Conclusion

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

In conclusion, this drug-target MR study identified PDE5 that had the potential to be repurposed as novel target for CHD and MI prevention, especially in protecting against MI among patients with CHD, and the underlying mechanisms of the effect might be partly involved in regulating blood pressure and LDL cholesterol.

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

Acknowledgments: The data used for the analyses described in this manuscript were obtained from the eQTLGen Consortium, GTEx Portal, Global Lipids Genetics Consortium, International Consortium of Blood Pressure, GIANT Consortium, MAGIC Consortium and CARDIoGRAMplusC4D Consortium on 01/07/2023. We thank the patients and investigators who contributed to these studies. **Ethical statement:** All publicly available genome-wide association studies (GWASs) and quantitative trait loci (QTLs) studies used in this MR analyses were approved by the relevant institutional review boards with informed consents from participants. Funding Information: This work was supported by National Natural Science Foundation of China (82304213) and Start-up Fund for high-level talents of Fujian Medical University (XRCZX2021026) to Dr. Wuqing Huang. The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication. **Author Contributors:** All authors were responsible for the study concept and design. WH obtained funding. JX did the statistical analysis. JX and WH drafted the manuscript, and all authors revised it for important intellectual content. **Competing interests:** The authors declare no conflict of interest.

References

365

- Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. British journal of pharmacology 2006;147 Suppl 1:S252-7.
- Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nature reviews Drug discovery 2014;13:290-314.
- Huang W, Sundquist J, Sundquist K, Ji J. Use of Phosphodiesterase 5 Inhibitors Is
 Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal
 Neoplasms. Gastroenterology 2019;157:672-681.e4.
- Hutchings DC, Anderson SG, Caldwell JL, Trafford AW. Phosphodiesterase-5 inhibitors
 and the heart: compound cardioprotection? Heart (British Cardiac Society)
 2018;104:1244-1250.
- Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH. Type 5
 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular
 disease. Cardiology in review 2007;15:76-86.
- Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacology & therapeutics 2015;147:12-21.
- Hashimoto T, Kim GE, Tunin RS et al. Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition. Circulation 2018;138:1974-1987.
- Nakano SJ, Miyamoto SD, Movsesian M, Nelson P, Stauffer BL, Sucharov CC. Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy. Circulation Heart failure 2015;8:57-63.
- 9. Pagani ED, Buchholz RA, Silver PJ. Cardiovascular cyclic nucleotide phosphodiesterases
 and their role in regulating cardiovascular function. Basic research in cardiology 1992;87
 Suppl 1:73-86.
- 389 10. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004;110:3149-55.
- Vinogradova TM, Lakatta EG. Dual Activation of Phosphodiesterase 3 and 4 Regulates
 Basal Cardiac Pacemaker Function and Beyond. International journal of molecular
 sciences 2021;22.
- 12. Leroy J, Fischmeister R. Inhibit a Phosphodiesterase to Treat Heart Failure? Circulation 2018;138:2003-2006.
- Roks AJM. Phosphodiesterase-1 in the cardiovascular system. Cellular signalling 2022;92:110251.
- 398 14. Bevan S, Porteous L, Sitzer M, Markus HS. Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis. Stroke 2005;36:949-53.
- 400 15. Lee DI, Zhu G, Sasaki T et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 2015;519:472-6.
- 402 16. Chen S, Zhang Y, Lighthouse JK et al. A Novel Role of Cyclic Nucleotide
 403 Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction. Circulation
 404 2020;141:217-233.
- 405 17. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. Journal of thrombosis and haemostasis: JTH 2012;10:167-76.
- Lugnier C, Meyer A, Talha S, Geny B. Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome? Pharmacology & therapeutics 2020;208:107475.
- 409 19. Gaziano L, Giambartolomei C, Pereira AC et al. Actionable druggable genome-wide 410 Mendelian randomization identifies repurposing opportunities for COVID-19. Nat Med 411 2021;27:668-676.

412	20.	Huang W, Xiao J, Ji J, Chen L. Association of lipid-lowering drugs with COVID-19
413		outcomes from a Mendelian randomization study, el ife 2021:10.

- Vosa U, Claringbould A, Westra HJ et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet 2021;53:1300-1310.
- 417 22. Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 2020;369:1318-1330.
- 419 23. McRae AF, Marioni RE, Shah S et al. Identification of 55,000 Replicated DNA Methylation 420 QTL. Sci Rep 2018;8:17605.
- 421 24. Nikpay M, Goel A, Won HH et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 2015;47:1121-1130.
- 25. Zhu Z, Zhang F, Hu H et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet 2016;48:481-7.
- Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol 2011;40:755-64.
- 427 27. Carter AR, Sanderson E, Hammerton G et al. Mendelian randomisation for mediation
 428 analysis: current methods and challenges for implementation. Eur J Epidemiol
 429 2021;36:465-478.
- 430 28. Nadur NF, de Azevedo LL, Caruso L, Graebin CS, Lacerda RB, Kümmerle AE. The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure. European journal of medicinal chemistry 2021;212:113123.
- 433 29. Andersson DP, Landucci L, Lagerros YT et al. Association of Phosphodiesterase-5
 434 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease. Journal
 435 of the American College of Cardiology 2021;77:1535-1550.
- 436 30. Gazzaruso C, Solerte SB, Pujia A et al. Erectile dysfunction as a predictor of
 437 cardiovascular events and death in diabetic patients with angiographically proven
 438 asymptomatic coronary artery disease: a potential protective role for statins and 5439 phosphodiesterase inhibitors. Journal of the American College of Cardiology
 440 2008;51:2040-4.
- Vestergaard N, Søgaard P, Torp-Pedersen C, Aasbjerg K. Relationship between
 treatment of erectile dysfunction and future risk of cardiovascular disease: A nationwide
 cohort study. European journal of preventive cardiology 2017;24:1498-1505.
- Johnstone TB, Smith KH, Koziol-White CJ et al. PDE8 Is Expressed in Human Airway
 Smooth Muscle and Selectively Regulates cAMP Signaling by beta(2)-Adrenergic
 Receptors and Adenylyl Cyclase 6. Am J Respir Cell Mol Biol 2018;58:530-541.

Wu XN, Zhou Q, Huang YD et al. Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementia.

Acta Pharm Sin B 2022;12:3103-3112.

Figure legends:

Figure 1. Flowchart of the study.

Figure 2. Association between the expression of PDEs in blood and coronary heart disease or myocardial infarction. (A) Coronary heart disease; (B) Myocardial infarction. * Shown in ascending order of p value.

Figure 3. Association between the expression of PDE5A or PDE8A in artery or heart tissue and coronary heart disease or myocardial infarction.

Figure 4. Association between the methylation of PDE5A or PDE8A and the gene expression in blood, coronary heart disease or myocardial infarction. (A) PDE5A; (B) PDE8A.

Figure 5. Two-step mendelian randomization between PDE5A expression, metabolic traits and coronary heart disease or myocardial infarction. (A) Coronary heart disease; (B) Myocardial infarction. * Percentage in plots indicates the proportion of mediated effect. The asterisk in plots indicates statistical significance (P<0.05).

Supplementary files:

Supplementary Table 1. Information of eQTL and GWAS summary data.

Supplementary Table 2. Information of PDE family.

Supplementary Table 3. SMR association between the expression of genes encoding PDEs in blood and coronary heart disease or myocardial infarction.

Supplementary Table 4. SMR association between the expression of PDE5A or PDE8A in artery or heart tissue and coronary heart disease or myocardial infarction.

Supplementary Table 5. The eQTL association between top SNP of PDE5A or PDE8A with the expression of other nearby genes.

Supplementary Table 6. SMR association between the expression of genes adjacent to PDE5A or PDE8A and coronary heart disease or myocardial infarction.

Supplementary Table 7. SMR association between the methylation of PDE5A and the PDE5A expression in blood, coronary heart disease or myocardial infarction.

Supplementary Table 8. SMR association between the methylation of PDE8A and the PDE8A expression in blood, coronary heart disease or myocardial infarction.

Supplementary Table 9. SMR association between the expression of PDE5A or PDE8A in blood and metabolic traits.

Supplementary Table 10. IVW-MR association between metabolic traits and coronary heart disease or myocardial infarction.

Supplementary Table 11. Two-step mendelian randomization between PDE5A expression in blood, metabolic traits and coronary heart disease or myocardial infarction.

Supplementary Figure 1. Tissue gene expression for PDE5A from GTEx Portal.

Supplementary Figure 2. Tissue gene expression for PDE8A from GTEx Portal.

Exposure:

Phosphodiesterases(PDEs)

Instruments using cis-eQTLs for the expression of genes coding PDEs

Secondary analysis 1: Tissue cis-eQTLs from GTEx Portal:

- Artery Aorta(N=387): 188 SNPs associated with expression of PDE5A
- Artery Tibial(N=372): 13 and 2 SNPs associated with expression of PDE5A and PDE8A respectively;
- Heart Atrial Appendage (N=584): 9 SNPs associated with expression of PDE5A

Primary analysis:

Blood cis-eQTLs from eQTLGen Consortium (N=31,684): 7,737 SNPs associated with expression of 17 genes coding PDE1-9

Secondary analysis 3:

Mediation of metabolic traits between expression of PDE5A/PDE8A and outcomes Instruments using cis-mQTLs for the methylation of genes coding PDEs

Secondary analysis 2:

Blood cis-mQTLs data from meta-analysis of two cohorts(N=1,980): 1,185 and 310 SNPs associated with PDE5- and PDE8-related methylation in 14 and 12 CpG sites respectively


Summary-data-based MR analysis Two-step MR analysis Sensitivity analyses

Outcomes: Coronary heart disease and myocardial infarction

GWAS data from CARDIoGRAMplusC4D Consortium

(A)

Exposure	Instrumental variant		OR (95% CI)	P
PDE5A	rs10518336	¦ ⊢■ →	1.22 (1.06-1.40)	4.56E-03
PDE8A	rs62022525	⊢ ■	1.26 (1.07-1.49)	4.66E-03
PDE6H	rs61041959	Ĥ ■ →	1.08 (0.99-1.18)	9.12E-02
PDE3B	rs12270702	+	1.13 (0.97-1.31)	1.20E-01
PDE6G	rs57135500	+■	1.09 (0.93-1.28)	2.92E-01
PDE2A	rs11235547		0.91 (0.76-1.10)	3.41E-01
PDE4B	rs12731764	■	0.91 (0.75-1.11)	3.49E-01
PDE4D	rs9291685	H = H	1.04 (0.95-1.13)	4.26E-01
PDE8B	rs163037	H al iph	0.98 (0.91-1.05)	5.25E-01
PDE9A	rs2839581	#	1.01 (0.98-1.04)	5.78E-01
PDE6D	rs838446	⊢■	0.98 (0.87-1.10)	6.95E-01
PDE1B	rs1874308	•	0.99 (0.94-1.04)	7.20E-01
PDE6B	rs4463020	⊢≢ ⊢	0.99 (0.89-1.10)	8.17E-01
PDE4A	rs77376335		0.99 (0.84-1.16)	8.71E-01
PDE7B	rs9389345	⊢	0.99 (0.76-1.28)	9.17E-01
PDE6C	rs11187583	· •	1.02 (0.72-1.43)	9.19E-01
PDE7A	rs62506599	———	1.00 (0.83-1.19)	9.58E-01
	0.6	5 0.8 1 1.2 1.4 1	.6	



(B)

Outcome	Exposure	Tissue	Instrumental varian	nt	OR (95% CI)	P
Coronary heart diseas	se			<u> </u>		
	PDE5A	Artery Aorta	rs1393966	⊢ ■	1.17 (1.05-1.32)	6.60E-03
		Heart Atrial Appendage	rs75098287	┝╼═─┤	1.20 (1.02-1.41)	3.12E-02
		Artery Tibial	rs111837430	- ∔- - ■	1.15 (0.96-1.38)	1.21E-01
	PDE8A	Artery Tibial	rs112008279	⊢■ →	1.20 (1.00-1.45)	5.23E-02
				İ		
Myocardial infarction						
	PDE5A	Artery Aorta	rs1393966	¦⊢ ■	1.15 (1.02-1.30)	2.69E-02
		Heart Atrial Appendage	rs75098287	├-■ ─-	1.18 (0.99-1.40)	6.67E-02
		Artery Tibial	rs111837430	- 	1.14 (0.94-1.39)	1.70E-01
	PDE8A	Artery Tibial	rs112008279	⊢	1.14 (0.93-1.39)	2.13E-01
				0.8 1 1.21.41	1 .6	

(A)

Exposure	Instrumental variant	Outcome		OR (95% CI)	P	
g18483704	rs66887589	DDECA america		> 4.04 (4.47.0.00)	4.455.07	
		PDE5A expression	_	1.84 (1.47-2.30)		
		Coronary heart disease		1.16 (1.05-1.30)		
~04770600	ro70000010	Myocardial infarction		1.19 (1.05-1.34)	5.50E-03	
01778622	rs79026312	DDE5A avarossion		■→ 1.57 (1.31-1.88)	0 725 07	
		PDE5A expression		1.20 (1.06-1.36)		
		Coronary heart disease Myocardial infarction		1.20 (1.06-1.37)		
g02673944	rs11098493	Myocardiai ililarciioii	-	1.20 (1.00-1.37)	3.70L-03	
902013344	1311030433	PDE5A expression		→ 1.44 (1.25-1.66)	4.07E.07	
		Coronary heart disease		1.17 (1.05-1.29)		
		Myocardial infarction		1.17 (1.05-1.29)		
15446520	rs13123289	Myocardia marchon		1.17 (1.00-1.01)	0.022-00	
910440020	1310120203	PDE5A expression		1.34 (1.17-1.54)	3 30F-05	
		Coronary heart disease		1.16 (1.03-1.29)		
		Myocardial infarction	ļ <u> </u>	1.19 (1.05-1.35)		
g07154408	rs10027976	my ocardial marchon	_	1.13 (1.05-1.00)	7.202-00	
		PDE5A expression	F -	→ 1.33 (1.17-1.51)	8.61E-06	
medRxiv pre preprint (which	print doi: https://doi.org/10.1101/20. was not certified by peer review) is	PDE5A expression 23.09.24.23296052; this version posted September 25, 2023. The co the author/funder, who has granted medRxiv a license to display the s reserved. No reuse allowed without permission.	pyright holder for this perpetuity.	1.17 (1.04-1.31)		
	All right	s reserved. No reuse allowed without permission. Myocardial infarction		1.20 (1.06-1.36)		
g09350414	rs28581362		**	(1.00)	1. 200-10 100 10.5.2	
		PDE5A expression	⊢	1.29 (1.18-1.41)	3.59E-08	
		Coronary heart disease	—	1.13 (1.04-1.22)		
		Myocardial infarction	⊢	1.15 (1.05-1.25)		
05550861	rs28581362	SCOT AND COMMENT OF THE COMMENT OF T		Granton A Granton consequence and Re-		
		PDE5A expression	⊢ ■	1.21 (1.14-1.28)	5.45E-10	
		Coronary heart disease	⊢ ■─	1.09 (1.03-1.16)		
		Myocardial infarction	→ ■ →	1.11 (1.04-1.18)		
g10183150	rs13139045		E E E			
<u> </u>		PDE5A expression	⊢ ■→	1.17 (1.11-1.23)	4.26E-10	
		Coronary heart disease	¦⊢ ■ →	1.07 (1.02-1.13)	2.92E-03	
		Myocardial infarction		1.07 (1.02-1.13)	7.23E-03	
g14736911	rs34624042		E E			
		PDE5A expression	⊢≣ ⊣	1.11 (1.08-1.14)	1.55E-13	
		Coronary heart disease	⊢	0.99 (0.96-1.02)	5.83E-01	
		Myocardial infarction	⊢	0.99 (0.96-1.02)	5.61E-01	
g24657788	rs61015834					
		PDE5A expression	⊢⊞ →	1.10 (1.06-1.13)	5.42E-10	
		Coronary heart disease	H B H	0.99 (0.96-1.02)	5.45E-01	
		Myocardial infarction	⊢	1.01 (0.98-1.05)	3.82E-01	
g08957091	rs11737400					
		PDE5A expression		0.79 (0.76-0.82)	1.52E-28	
		Coronary heart disease	H	0.95 (0.92-0.98)	4.42E-03	
		Myocardial infarction -		0.94 (0.90-0.98)	1.81E-03	
g21123740	rs12505735					
		PDE5A expression		0.83 (0.79-0.87)		
			■ →	0.92 (0.88-0.97)		
		Myocardial infarction	■	0.93 (0.88-0.98)	8.96E-03	
26975461	rs10213342					
		PDE5A expression	i i	0.90 (0.87-0.92)		
		Coronary heart disease	+■ →	0.96 (0.94-0.99)		
		Myocardial infarction	H	0.96 (0.93-0.99)	3.14E-03	
g16056087	rs6832410					
		PDE5A expression		0.90 (0.88-0.93)		
		orienal production	+	0.95 (0.92-0.98)		
		Myocardial infarction	⊢≣ → '	0.94 (0.91-0.98)	1 24F-03	

.81E-03						
50E-03	Exposure	Instrumental variant	Outcome		OR (95% CI)	Р
	cg10587940	rs12905036				
73E-07			PDE8A expression	<u> </u>	1.21 (1.11-1.32)	7.71E-0
27E-03			Coronary heart disease	⊢ ■	1.17 (1.07-1.28)	8.84E-0
'8E-03			Myocardial infarction	- ■	1.19 (1.08-1.32)	7.88E-0
	cg09425164	rs34731527				
7E-07			PDE8A expression	⊢ ■	1.20 (1.16-1.24)	1.94E-2
79E-03			Coronary heart disease	⊢≣ 1	1.06 (1.02-1.10)	9.23E-
2E-03			Myocardial infarction	⊢ ■	1.06 (1.03-1.11)	1.18E-
	cg25941682	rs11631171				
0E-05			PDE8A expression	■	1.14 (1.09-1.19)	2.43E-
8E-02			Coronary heart disease	⊢	0.98 (0.93-1.03)	3.65E-
5E-03			Myocardial infarction	———	0.98 (0.92-1.04)	4.94E-
	cg17133734	rs1533125		7 * 4 & Lis Lis		
1E-06			PDE8A expression	⊢ ■	1.11 (1.07-1.16)	4.82E-
2E-03			Coronary heart disease	⊢■ →	1.06 (1.01-1.11)	2.95E-
1E-03			Myocardial infarction	⊢ ■1	1.07 (1.02-1.13)	
	cg19183879	rs925412	Control of the second state of the second se	List of the second seco	5 CORE (S. L. V. CORC) C. C. O. O. S. P.C. V.	
9E-08	3		PDE8A expression	,≡ -1	1.07 (1.05-1.10)	1.14E-
0E-03			Coronary heart disease	- 	1.04 (1.00-1.07)	
5E-03			Myocardial infarction		1.05 (1.01-1.09)	
	cg11038343	rs8040292	,	COMMITTEE COMMIT	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
5E-10	og . 10000 10	100010202	PDE8A expression	1■ -1	1.07 (1.05-1.10)	6.74E-
4E-03			Coronary heart disease		1.03 (1.00-1.06)	
5E-03			Myocardial infarction		1.03 (1.00-1.07)	
	cg02903680	rs7173332	,		,	
6E-10	3		PDE8A expression ←■──		0.66 (0.58-0.75)	6.28E-
2E-03				■	0.88 (0.81-0.96)	
3E-03			1000		0.88 (0.80-0.96)	
	cg02913089	rs896364	,		,	
5E-13	3		PDE8A expression ←■		0.66 (0.58-0.75)	1 29F-
3E-01			Coronary heart disease	⊢ ■	0.90 (0.83-0.98)	
1E-01					0.89 (0.81-0.98)	
	cg15029032	rs55649640	,		0.00 (0.01 0.00)	
2E-10	0910020002	1000010010	PDE8A expression		0.77 (0.68-0.87)	3 41F-
5E-01			Coronary heart disease	⊢ ■	0.96 (0.88-1.06)	
2E-01			Myocardial infarction		0.99 (0.88-1.10)	
	cg25846076	rs289384	my ocal alai miai ca on		0.00 (0.00 1.10)	0
2E-28	0920010010	10200001	PDE8A expression		0.81 (0.74-0.88)	1 93F-
2E-03			Coronary heart disease	-	0.97 (0.90-1.04)	
1E-03			Myocardial infarction	⊢ ■-	0.95 (0.88-1.04)	
.2 00	cg19686637	rs72759100	my ocar arar mar or on	— I	0.00 (0.00 1.01)	
4E-12	cg (500000)	13/2/03/00	PDE8A expression	-	0.85 (0.80-0.90)	1 43F-
9E-03			Coronary heart disease		1.02 (0.96-1.08)	
6E-03			Myocardial infarction		1.02 (0.96-1.09)	
-UJ	cg23334467	rs58943832	myocardia miarcion		1.02 (0.30-1.03)	T.31L-
3E-19	cy25554407	1550545052	PDE8A expression	⊢	0.86 (0.81-0.91)	3 70⊏
			Coronary heart disease		0.97 (0.92-1.02)	
33E-03						
14E-03			Myocardial infarction		0.96 (0.91-1.02)	1.99E-
EE 44			0.6 0.8	8 1 1.2 1.4	1.6	
95E-11						

